Protagonist Therapeutics (NASDAQ:PTGX) Given New $100.00 Price Target at TD Cowen

Protagonist Therapeutics (NASDAQ:PTGX) had its target price hoisted by TD Cowen from $90.00 to $100.00 in a research report report published on Thursday,Benzinga reports. TD Cowen currently has a buy rating on the stock.

Several other analysts have also recently issued reports on PTGX. Citizens Jmp increased their price target on shares of Protagonist Therapeutics from $102.00 to $112.00 and gave the stock a “market outperform” rating in a research report on Thursday. Barclays increased their target price on shares of Protagonist Therapeutics from $108.00 to $113.00 and gave the stock an “overweight” rating in a report on Thursday. JPMorgan Chase & Co. boosted their price target on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Truist Financial increased their price objective on Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Finally, HC Wainwright lifted their target price on Protagonist Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $99.31.

Protagonist Therapeutics Stock Up 1.5%

NASDAQ:PTGX opened at $88.39 on Thursday. Protagonist Therapeutics has a 52 week low of $35.95 and a 52 week high of $96.54. The stock’s fifty day moving average is $84.12 and its two-hundred day moving average is $76.59. The stock has a market capitalization of $5.53 billion, a price-to-earnings ratio of -43.12 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). The firm had revenue of $7.44 million during the quarter, compared to analyst estimates of $14.92 million. Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.50%. On average, sell-side analysts expect that Protagonist Therapeutics will post 2.43 EPS for the current fiscal year.

Insider Activity at Protagonist Therapeutics

In related news, Director Lewis T. Williams sold 18,000 shares of Protagonist Therapeutics stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $82.42, for a total transaction of $1,483,560.00. Following the sale, the director directly owned 7,825 shares in the company, valued at $644,936.50. This trade represents a 69.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William D. Waddill sold 20,000 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the completion of the sale, the director directly owned 7,825 shares of the company’s stock, valued at approximately $654,796. This trade represents a 71.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 203,167 shares of company stock valued at $16,889,199 in the last quarter. Company insiders own 4.90% of the company’s stock.

Institutional Investors Weigh In On Protagonist Therapeutics

Several large investors have recently modified their holdings of PTGX. American Century Companies Inc. lifted its holdings in shares of Protagonist Therapeutics by 18.7% during the second quarter. American Century Companies Inc. now owns 813,995 shares of the company’s stock worth $44,990,000 after purchasing an additional 128,171 shares during the period. Voya Investment Management LLC raised its position in Protagonist Therapeutics by 8.9% during the 3rd quarter. Voya Investment Management LLC now owns 305,419 shares of the company’s stock worth $20,289,000 after buying an additional 25,065 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new stake in shares of Protagonist Therapeutics in the 2nd quarter worth $6,641,000. Nan Fung Trinity HK Ltd. purchased a new stake in shares of Protagonist Therapeutics in the second quarter valued at about $7,464,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Protagonist Therapeutics by 3.0% during the second quarter. Bank of New York Mellon Corp now owns 388,082 shares of the company’s stock worth $21,449,000 after acquiring an additional 11,219 shares during the period. 98.63% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: Several brokers raised ratings and price targets this morning, signaling renewed analyst conviction (higher targets increase upside perception). Barclays raised its target to $113 and kept an “overweight” rating. Barclays Raises PT to $113
• Positive Sentiment: Citizens JMP bumped its target to $112 and maintained a “market outperform” view, adding to the upward pressure on investor expectations. Citizens JMP Raises PT to $112
• Positive Sentiment: TD Cowen raised its target to $100 and reaffirmed a “buy” rating, giving additional dealer support for further gains. TD Cowen Raises PT to $100
• Positive Sentiment: Company corporate update: Protagonist submitted an NDA for rusfertide to the FDA (potential approval/launch this year), expects a U.S. regulatory decision for ICOTYDE (icotrokinra) in 2026 with potential launch, may opt out of a 50:50 profit/loss sharing deal with Takeda (90‑day window expected in Q2), expects PN‑881 Phase 1 completion by mid‑2026, and expanded its preclinical pipeline — all items that materially improve medium‑term commercial and revenue prospects. Corporate Update / Correction
• Neutral Sentiment: Press coverage and earnings snapshot pieces summarizing the quarter and corporate update provide broader market context but add no new facts beyond the company release. Q4 Earnings Snapshot
• Negative Sentiment: Q4 results missed expectations: reported EPS of ($0.69) vs. consensus ($0.53) and revenue $7.44M vs. $14.92M est. The revenue shortfall and EPS miss add short‑term execution risk and raise questions about near‑term cash flow. Q4 Results / Press Release
• Negative Sentiment: Hedge fund BVF disclosed a large Q4 exit, selling ~2.56M PTGX shares (≈$170M at quarter‑end), which could increase supply pressure if other holders follow. BVF Share Sale

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.